- Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
Pauline Rottier et al, 2023, Frontiers in Oncology CrossRef - Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
Wei Wang et al, 2023, Technology in Cancer Research & Treatment CrossRef - Pediatric brain tumor patients display altered immune activation and reduced lymphopoiesis at the onset of disease
Marco Rosichini et al, 2024, npj Precision Oncology CrossRef - The prognostic value of absolute lymphocyte count and neutrophil‐to‐lymphocyte ratio for patients with metastatic breast cancer: a systematic review and meta‐analysis
Bulin Sang et al, 2024, Frontiers in Oncology CrossRef - Effect of Radiation Therapy on Composition of Lymphocyte Populations in Patients with Primary Breast Cancer
Irina Kobzeva et al, 2023, Journal of Personalized Medicine CrossRef - Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer
Takayuki Kobayashi et al, 2024, BMC Cancer CrossRef - Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
Alberto D’Angelo et al, 2022, Current Issues in Molecular Biology CrossRef - Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
Wei Wang et al, 2024, BMC Cancer CrossRef - Systemic Inflammatory Response as a Prognostic Factor in Breast Cancer. Part II. Hematological Markers of Inflammation
Natalia S. Sergeeva et al, 2023, Annals of the Russian academy of medical sciences CrossRef